Atopic dermatitis (AD) is a chronic skin condition affecting around 2.5 million French people, or almost 5% of the population. This skin condition, which ranks as the second most common skin disease after acne, represents a real medical challenge. Indeed, with only 5 dermatologists per 100,000 inhabitants in France, many patients suffering from Atopic Dermatitis are confronted with long waiting times and therapeutic wandering. However, thanks to the advent of new technologies and telemedicine, an innovative solution is about to emerge to improve care for these patients: PixaDA.
Pixacare has won Biovalley France's call for projects aimed at optimizing the care of patients suffering from Atopic Dermatitis. This medtech company plans to develop an innovative solution called PixaDA, offering two distinct applications: one for patients and one for healthcare professionals.
The patient app enables photographic and medical monitoring of the evolution of their Atopic Dermatitis. Thanks to this application, patients can take photos at each flare-up and fill in questionnaires to document symptoms, severity, itching intensity and other relevant information. They also have access to a dashboard displaying the pathology's evolution curves, as well as the possibility of generating a follow-up report for their next medical appointment.
What's more, the PixaDA application offers therapeutic education content tailored to the severity of each patient's Atopic Dermatitis, as well as referrals to nearby centers of expertise.
For healthcare professionals, the PixaDA application enables collaborative telemonitoring. Dermatologists and referring physicians can prescribe remote monitoring and communicate with their patients via a secure messaging system. This direct, rapid communication avoids lengthy waiting times, and enables treatments to be adapted as the disease progresses. What's more, thanks to emergency notifications, complications can be detected more quickly, offering greater responsiveness.
Pixacare offers numerous benefits for patients, caregivers, hospitals and the healthcare system as a whole.
Firstly, Atopic Dermatitis patients can access specific therapeutic content to better understand and manage their condition. They also benefit from faster treatment thanks to direct communication with their dermatologist, avoiding long waiting times for consultations.
In addition, caregivers such as GPs, dermatologists, pharmacists and other healthcare professionals can coordinate their actions more effectively, promoting a multidisciplinary approach to patient care. Hospitals also benefit from the structuring and securing of medical data, reducing the number of emergency consultations.
Finally, the healthcare system as a whole is seeing a reduction in the cost of caring for patients with Atopic Dermatitis, thanks to better disease management and optimized treatments.
Pixacare has won the Défis Santé Numérique 2021 award for its PixaDA solution, designed to improve care for patients suffering from Atopic Dermatitis. This innovative solution offers photographic and medical monitoring of disease progression, direct communication between patients and dermatologists, and collaborative remote monitoring between all players in the care pathway. The benefits of PixaDA for patients, caregivers, hospitals and the healthcare system are numerous. Pixacare plans a first test of its solution in September 2024, followed by a full roll-out in 2024.
We would like to thank our partners, Biovalley, the French Eczema Association Stephanie Merhand, the GET (education group) of the SFD ASD, and Lilly France for their support and confidence in this project. Thanks to them, we're proud to be able to help reduce the number of patients with Atopic Dermatitis wandering from one treatment to another, and improve their quality of life.
